Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study

Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study
Adding ipatasertib to standard treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly extended survival without disease worsening in a group of men whose tumors lack the PTEN protein, a Phase 3 clinical trial found. But the combination, which included ipatasertib plus standard Zytiga (abiraterone acetate) and prednisone/prednisolone, failed to extend the time without disease progression or death in the overall mCRPC population, the researchers noted. “The early results of the IPATential150 study are encouraging in our ongoing mission to develop new treatment options for people with advanced prostate cancer,” Levi Garraway, MD, PhD, chief medical officer and head of global product development, said in a press release. Ipatasertib, developed by Genentech, is an oral investigational medicine that works by binding and blocking the A
Subscribe or to access all post and page content.